Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10698842 | 0.87 | MAPT (0.54) | MAPTHPGDSRD5A1PDE3BPDE3A | |
| SCHEMBL12992155 | 0.75 | MAPT (0.51) | MAPTHPGDAADAT | |
| SCHEMBL1744184 | 0.73 | CYP11B2 (0.40) | SRD5A1PDE3BPDE3A | |
| SCHEMBL30896361 | 0.73 | CYP11B2 (0.40) | SRD5A1PDE3BPDE3A | |
| SCHEMBL31714295 | 0.71 | MAPT (0.42) | MAPTHPGD | |
| SCHEMBL31714604 | 0.71 | — | — | |
| SCHEMBL29290373 | 0.71 | MAPT (0.57) | MAPTHPGD | |
| SCHEMBL18569594 | 0.70 | MAPT (0.52) | MAPTHPGDSRD5A1AADAT | |
| SCHEMBL31714530 | 0.70 | CYP19A1 (0.32) | MAPT | |
| SCHEMBL28250154 | 0.69 | ACHE (0.53) | MAPTHPGDSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | MAPT 4543/4885HPGD 387/4885SRD5A1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.